RxDoctor Payments Data

Jacqueline Hines-Kruse, PA

Physician Assistant · Ritzville, WANPI 1316565708

Payments from drug & device makers

$2,432in general payments, 2019–2025

Across 58 payments — averaging $41.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$474
  • Medtronic$307
  • Lilly USA, LLC$282
  • GSK$210
  • Corcept Therapeutics$191
  • Boehringer Ingelheim$160
  • plus $809 from 17 others

What the payments were for

  • Food & beverage$2,40999%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,432 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$17,870
Medicare patients
106
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$70,322
JardianceEmpagliflozin22$37,590
EliquisApixaban18$28,325
XareltoRivaroxaban23$24,728
FarxigaDapagliflozin Propanediol15$24,228
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,047
TrulicityDulaglutide13$12,561
Tresiba Flextouch U-100Insulin Degludec14$10,613
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,645
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,610
Omeprazole128$3,096
Levemir FlexpenInsulin Detemir15$2,427
Pantoprazole Sodium28$1,461
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,415
Levothyroxine Sodium155$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$474$70,32254 claims
Boehringer IngelheimJardiance$160$37,59022 claims
PfizerEliquis$106$28,32518 claims
GSKTrelegy Ellipta, Anoro Ellipta$210$25,69336 claims
Johnson & JohnsonXarelto$51$24,72823 claims
Lilly USA, LLCTrulicity$282$12,56113 claims
AbbVieSynthroid$18$1,14222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Ritzville

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →